RxDoctor Payments Data

Manish Patel, DO

Family Medicine · Spring, TXNPI 1922056357

Payments from drug & device makers

$923in general payments, 2019–2025

Across 32 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$340
  • Inspire Medical Systems, Inc.$279
  • Pfizer$70
  • Novartis$42
  • GSK$34
  • Eisai Inc.$30
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$923 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,615
Medicare patients
43
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$60,374
OzempicSemaglutide29$37,978
EliquisApixaban15$10,926
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,021
Gabapentin111$2,121
Albuterol Sulfate HfaAlbuterol Sulfate72$1,565
Ventolin HfaAlbuterol Sulfate16$1,371
Lisinopril179$1,169
Bupropion XlBupropion Hcl27$1,163
Atorvastatin Calcium138$1,117
Fluticasone Propionate62$913
Hydroxyzine Hcl53$811
ConstuloseLactulose15$776
Amitriptyline Hcl29$757
Levothyroxine Sodium71$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$13$60,37434 claims
Novo NordiskOzempic$340$37,97829 claims
PfizerEliquis$70$10,92615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →